Detect common and complex biomarkers across 300+ genes, including genomic signatures like bTMB
Identify clonal hematopoesis vs. tumor-derived variant calls using Foundation Medicine's research use capabilities
Cast a wide net for potential responders by leveraging exploratory, blood based assays
Understand more about your target population with real-world datasets and visualization tools
Liquid Biopsy Clinical Trial Assays and ctDNA Monitoring Solutions
Challenge your liquid biopsy expectations: Foundation Medicine’s ctDNA tumor fraction offers more confidence in negative results so that you can harness the convenience of liquid with greater concordance to tissue. Learn more about ctDNA tumor fraction here
Assess treatment response faster than standard imaging.3 Learn more about Foundation Medicine’s ctDNA monitoring portfolio here
Global Regulatory & Commercial Solutions
Don’t risk asynchronous drug and diagnostic approvals; Foundation Medicine is the global leader in approved CDx indications for liquid biopsy CGP testing
Unlock your global launch strategies with comprehensive global regulatory experience, including IVDR
Enable timely physician engagement for patient treatment planning with new data solutions
Want to Learn More?
Gromova M et al. Biomark Insights. 2020;15:1177271920974652
